Disseminated Intravascular Coagulation

Tissue Factor (TF) Release and Extrinsic Pathway Activation

• Massive systemic release of tissue factor from damaged endothelial cells, activated monocytes/macrophages, or tumor cells initiates the extrinsic coagulation pathway
• TF binds Factor VII (which becomes activated to Factor VIIa) on the surface of phosphatidylserine-expressing cells, forming the TF-Factor VIIa complex
• This complex catalyzes formation of Factor IXa and Factor Xa, amplifying coagulation cascade activation far beyond normal hemostatic needs
• In sepsis, lipopolysaccharide (LPS) directly upregulates TF expression on monocytes and endothelial cells via toll-like receptor-4 (TLR4) signaling
• In APL, the PML-RARA fusion protein drives aberrant expression of annexin II and other procoagulants on leukemic blasts
• This generates thrombin in excessive amounts throughout the vascular compartment rather than at sites of vascular injury

Thrombin Generation, Amplification, and Platelet Activation

• Massive thrombin (Factor IIa) generation activates platelets through protease-activated receptors (PAR-1, PAR-4), causing shape change, granule secretion, and aggregation
• Activated platelets expose phosphatidylserine on their outer membrane, providing a negatively charged surface that further amplifies coagulation cascade reactions
• Thrombin also activates Factor V, Factor VIII, Factor XI, and Factor XIII, creating a positive feedback amplification loop
• Factor XIII cross-links fibrin monomers into stabilized clots, creating microthrombi that lodge in multiple organ beds (brain, lungs, kidneys, skin, liver)
• Platelet aggregation and fibrin deposition consume massive quantities of circulating platelets (thrombocytopenia develops within hours to days)

Fibrinogen Consumption and Secondary Fibrinolysis

• Excessive thrombin cleaves fibrinogen into fibrin monomers at rates far exceeding supply, causing fibrinogen levels to drop precipitously (often <100 mg/dL; normal 200-400 mg/dL)
• Fibrin degradation products (FDPs), including the characteristic D-dimer, accumulate at concentrations 5-100× normal values
• Tissue plasminogen activator (tPA) is released from endothelial cells in response to thrombin and inflammatory cytokines, activating plasminogen to plasmin
• Plasmin attempts to dissolve the massive fibrin burden but also degrades fibrinogen directly and inactivates Factors V and VIII, paradoxically promoting bleeding
• This produces primary fibrinolysis that overwhelms protective fibrinolysis, resulting in bleeding despite ongoing thrombosis—the defining clinical paradox

Endothelial Dysfunction and Inflammatory Amplification

• Systemic release of TNF-α, IL-6, IL-8, and other inflammatory cytokines (especially in sepsis-induced DIC) directly damages endothelial cells and increases vascular permeability
• Thrombin itself activates endothelial cells through PAR-1, driving further TF expression and release of von Willebrand factor (vWF) and P-selectin
• Complement activation (C3a, C5a) by bacterial endotoxin or tumor antigens amplifies endothelial injury and promotes leukocyte infiltration into tissues
• Loss of endothelial integrity permits extravasation of microthrombi and hemorrhage, creating the characteristic clinical picture of bleeding at catheter sites, mucosal surfaces, and skin
• Platelet and endothelial cell microparticles (phosphatidylserine-positive vesicles) are released into circulation and directly propagate coagulation activation

Consumption Coagulopathy and Factor Depletion

• Consumption of platelets, fibrinogen, Factors II, V, VIII, X, and XIII occurs as these hemostatic components are incorporated into microthrombi or consumed by ongoing thrombin generation
• Antithrombin III (ATIII) becomes depleted as it is consumed by binding to excess thrombin and activated coagulation factors
• Protein C and Protein S levels fall due to consumption and decreased hepatic synthesis in critical illness
• This creates a state of paradoxical procoagulance (unable to generate new clots despite ongoing thrombosis) combined with hypocoagulability (unable to stop bleeding despite platelet consumption)

Organ-Level Microvascular Sequelae

• Microthrombi occlude capillaries and small vessels, causing ischemic damage in the kidneys (acute kidney injury with schistocytes on blood smear), lungs (ARDS), brain (encephalopathy), skin (necrosis), and liver (hepatic dysfunction)
• Microvascular obstruction triggers local inflammatory responses and tissue hypoxia, perpetuating endothelial injury
• Red blood cells are mechanically damaged as they traverse partially occluded vessels, producing fragmented RBCs (schistocytes) visible on peripheral smear and contributing to microangiopathic hemolytic anemia

Severe Infection/Sepsis (Most Common)

• Gram-negative sepsis (particularly with meningococcemia, E. coli, Pseudomonas) presents as the single most common cause of DIC; occurs in 30-50% of septic patients
• Gram-positive sepsis (S. aureus, Streptococcus pneumoniae) and fungal infections (Aspergillus, Candida) also frequently trigger DIC
• Viral infections including COVID-19, dengue fever, and varicella-zoster can precipitate DIC through similar mechanisms of endothelial injury and TF release
• Malaria, particularly P. falciparum, causes DIC through massive parasitemia and RBC destruction
• Mechanism: bacterial endotoxin (LPS) and exotoxins directly upregulate TF on monocytes and activate complement; pathogen-associated molecular patterns (PAMPs) trigger TLR signaling

Hematologic Malignancy (Second Most Common)

• Acute promyelocytic leukemia (APL, M3 subtype) is the most frequent hematologic cause, with DIC present in 80-90% of cases at diagnosis
• APL leukemic blasts express extremely high levels of tissue factor and cancer procoagulant (alternative coagulation pathway activator) on their surface
• Other acute myeloid leukemias (AML), particularly monocytic variants (M4, M5), similarly express high TF levels
• Acute lymphoblastic leukemia (ALL) and lymphomas cause DIC less commonly but more severe when present
• Mechanism: malignant cells directly release procoagulant material and trigger production of inflammatory cytokines by normal cells

Solid Malignancy

• Adenocarcinomas (lung, gastric, pancreatic, breast, ovarian, prostate) frequently cause DIC; mucinous adenocarcinomas particularly notorious
• Cancer cells express TF and cancer procoagulant; tumor necrosis releases cellular debris and microparticles rich in phosphatidylserine
• Metastatic disease with high tumor burden carries greatest risk; occurs in 5-30% of advanced malignancy cases
• Chemotherapy-induced DIC can occur during initial tumor lysis in highly chemosensitive tumors (especially lymphomas and ALL)

Obstetric Complications

• Placental abruption is the most common obstetric cause, occurring in 10-20% of abruption cases; amniotic fluid entry into maternal circulation releases tissue factor and triggers systemic coagulation
• Amniotic fluid embolism causes fulminant DIC with high mortality (60-80%); amniotic fluid contains procoagulant material and fetal cells expressing high TF levels
• Preeclampsia/eclampsia and HELLP syndrome cause DIC through endothelial damage and placental insufficiency
• Acute fatty liver of pregnancy triggers DIC through hepatic injury and release of cellular contents
• Retained dead fetus syndrome develops insidiously over weeks as dead fetal tissue releases thromboplastic material into maternal circulation

Severe Trauma and Burns

• Massive tissue injury releases tissue factor directly into circulation in quantities proportional to injury severity
• Blast injuries, crush injuries, and extensive burns trigger DIC through combined TF release, hypoxia, shock, and secondary sepsis
• Risk increases with injury severity score (ISS) >20 and Abbreviated Injury Scale (AIS) scores reflecting severe central nervous system or liver injury
• Occurs in approximately 3-10% of trauma patients but in up to 50% of severely polytrauma patients

Acute Promyelocytic Leukemia (APL) and Acute Leukemia

• APL carries the highest baseline risk of DIC of any malignancy; even before chemotherapy initiation, 80-90% of patients have laboratory evidence of DIC
• Leukemic blasts display extremely high-level expression of annexin II and phosphatidylserine, creating a procoagulant surface
• PML-RARA fusion protein (t(15;17) translocation) drives expression of these procoagulant molecules
• All-trans retinoic acid (ATRA) therapy, while curative for APL, can paradoxically worsen DIC during initial treatment due to blast differentiation and release of preformed granule contents
• Arsenic trioxide therapy is associated with lower rates of ATRA-related DIC exacerbation

Venom-Induced Coagulopathy

• Snake venom (certain vipers and elapids) contains enzymes (serine proteases) that directly activate coagulation factors, bypassing normal regulation
• Spider venom and insect venom can similarly trigger coagulation activation
• Mechanism differs from infectious/malignant DIC but produces similar consumption coagulopathy picture

Severe Liver Disease

• Cirrhosis with portal hypertension and acute liver failure cause DIC through decreased hepatic synthesis of anticoagulants (protein C, protein S, antithrombin III)
• Combined with portal hypertension-induced splenomegaly and platelet sequestration, this creates severe hemostatic derangement
• Direct hepatocellular injury releases tissue factor from damaged hepatocytes
• Reactivation of latent infections (hepatitis B, hepatitis C) can trigger acute DIC superimposed on chronic liver disease

Additional Risk Factors and Causes

• Severe hemolytic transfusion reaction releases hemoglobin and red cell stroma containing phosphatidylserine
• Heat stroke and hyperthermia cause direct endothelial injury and cytokine release
• Acute pancreatitis releases pancreatic enzymes and TF-rich pancreatic lipid into circulation
• Artificial heart devices and severe atherosclerotic disease can trigger chronic or subacute DIC through continuous endothelial damage
• Acute intravascular hemolysis (massive transfusion, autoimmune hemolytic anemia) causes TF release from RBC membranes and hemoglobin-mediated endothelial damage

Hemorrhagic Manifestations (Bleeding Diathesis)

• Spontaneous bleeding from multiple sites occurs due to severe consumption of platelets, fibrinogen, and clotting factors; typically appears suddenly in a previously stable patient
• Mucosal bleeding: gingival bleeding, epistaxis, hemoptysis, gastrointestinal bleeding, and hematuria develop as platelet counts fall and fibrinogen becomes severely depleted
• Skin hemorrhage: petechae and purpura appear on dependent areas and areas of pressure (buttocks, lower extremities, skinfolds); may be extensive and coalescing; the term "purpura fulminans" describes rapidly progressive, extensive cutaneous necrosis with underlying thrombosis (particularly in meningococcemia)
• Bleeding from catheter sites, venipuncture sites, and surgical wounds occurs out of proportion to the degree of intervention, reflecting global coagulopathy
• Intracranial hemorrhage (subdural hematoma, intracerebral hemorrhage, subarachnoid hemorrhage) represents a catastrophic complication with high mortality
• Gastrointestinal hemorrhage can be massive, requiring transfusion and often reflecting both DIC-related coagulopathy and direct gastrointestinal involvement by microthrombi
• Bleeding tends to be early manifestation (hours to days) and often precedes thrombotic manifestations

Thrombotic and Microvascular Manifestations (Paradoxical Despite Bleeding)

• Microvascular thrombosis creates characteristic organ ischemia despite the bleeding tendency—a pathognomonic feature that distinguishes DIC from simple coagulopathy
• Acute kidney injury (AKI): microthrombi lodge in renal glomeruli and arterioles, causing acute tubular necrosis (ATN) with oliguria; creatinine rises rapidly (often by 1-2 mg/dL per 24 hours); urine shows RBCs and RBC casts reflecting glomerular damage; approximately 50% of DIC patients develop renal dysfunction
• Acute respiratory distress syndrome (ARDS): microthrombi in pulmonary capillaries cause diffuse alveolar damage, triggering ARDS with bilateral infiltrates, hypoxemia (PaO2/FiO2 ratio <200), and difficulty with mechanical ventilation
• Digital/extremity ischemia and gangrene: peripheral microthrombi cause finger and toe necrosis, often with sharp demarcation; toes/fingers appear mottled or black; may require amputation if DIC not rapidly reversed
• Skin necrosis: focal areas of skin death appear, particularly on extremities, buttocks, and nose; the combination of bleeding (purpura) with adjacent necrosis is highly characteristic
• Acral necrosis: blackening of fingers, toes, ears, and nose tips from microinfarction; particularly dramatic in meningococcemia with purpura fulminans
• Thrombosis of specific vascular beds: hepatic vein thrombosis (causing hepatic dysfunction), mesenteric thrombosis (bowel ischemia), cerebral thrombosis (stroke), and retinal artery thrombosis all documented

Central Nervous System Manifestations

• Encephalopathy: confusion, disorientation, agitation, or lethargy occurs from combination of sepsis, hypoxia, direct cerebral microthrombi, and metabolic derangement
• Focal neurologic deficits: stroke syndromes from cerebral microthrombi; intracranial hemorrhage causing focal weakness, speech difficulties, or loss of consciousness
• Seizures: may result from direct cerebral involvement or metabolic derangement

Systemic Signs of Critical Illness

• Fever: nearly universal in infectious DIC; often very high (>39°C) reflecting severe infection
• Hypotension and shock: from sepsis, massive hemorrhage, or vasodilatation from inflammatory mediators; requires vasopressor support
• Tachycardia: compensatory response to hypotension and tissue hypoxia; often >120 bpm
• Tachypnea: from acidosis, hypoxia, or ARDS; respiratory rate often >20-30 breaths/min

Physical Examination Findings

• Purpura/petechiae: small red-purple non-blanching macules, typically on lower extremities, buttocks, and pressure areas; may be clustered or form larger ecchymoses
• Purpura fulminans: extensive areas of confluent purple discoloration with rapid darkening

Initial panel (order all four together)

• Platelet count: falling or low; a downward trend on serial CBCs is more informative than any single value, because consumption is dynamic.
• PT/INR and aPTT: prolonged from consumption of factors II, V, VIII, and X; PT prolongs earliest because of factor VII's short half-life.
• Fibrinogen: low, but it is an acute-phase reactant, so a "normal" fibrinogen in a septic or pregnant patient may represent a large relative drop — trend it.
• D-dimer / fibrin-related markers: markedly elevated; the most sensitive single test, but non-specific (elevated in VTE, surgery, malignancy, pregnancy).

Supporting studies

• Peripheral smear: schistocytes (helmet cells, fragments) from mechanical shearing across fibrin strands — present in only about half of cases and never sufficient alone.
• Antithrombin, protein C, factor V and VIII levels: all consumed. A low factor VIII is the classic discriminator from liver disease, where factor VIII (endothelially synthesized) is preserved or high.
• Haptoglobin low, LDH and indirect bilirubin high: microangiopathic hemolysis.

Scoring

• ISTH overt-DIC score is the named system, applied only when a predisposing condition is present. It assigns points for platelet count (<100 and <50 ×10⁹/L), elevation of a fibrin marker such as D-dimer (moderate vs strong rise), PT prolongation (≥3 s and >6 s), and fibrinogen below 100 mg/dL. A total ≥5 is compatible with overt DIC; <5 suggests non-overt DIC and warrants repeat scoring in 1–2 days.
• The JAAM and JSTH criteria exist and add organ-failure/SIRS variables; ISTH is the version tested.

Immediate stabilization

• Source control and antimicrobials for sepsis, per the Surviving Sepsis Campaign: cultures then broad-spectrum antibiotics without delay, plus resuscitation and vasopressors as needed.
• Obstetric triggers: evacuation of the uterus/delivery is definitive for abruption and retained fetus (ACOG); coagulopathy typically resolves within hours of delivery.
• Suspected APL: start **all-*trans* retinoic acid (ATRA) immediately on clinical suspicion**, before cytogenetic confirmation — NCCN AML guidance. Delay costs lives from intracranial hemorrhage.

Blood product support — transfuse the bleeding patient, not the number

• Platelets: for active bleeding or pre-procedure, generally at counts below ~50 ×10⁹/L; prophylaxis in non-bleeding patients is reserved for severe thrombocytopenia at high hemorrhagic risk.
• Fresh frozen plasma: for bleeding with significantly prolonged PT/aPTT; volume overload limits its use.
• Cryoprecipitate or fibrinogen concentrate: for bleeding with fibrinogen below roughly 150 mg/dL — fibrinogen replacement is often the highest-yield product.
• Prothrombin complex concentrate is a second-line option when volume cannot be tolerated, recognizing it lacks fibrinogen and factor V.

Anticoagulation

• Therapeutic heparin (UFH or LMWH) is reserved for thrombosis-predominant DIC — purpura fulminans, acral ischemia, large-vessel or Trousseau-syndrome thrombosis — and is titrated cautiously.
• Prophylactic-dose LMWH for VTE prevention in critically ill, non-bleeding DIC patients.

Contraindicated / avoid

• Antifibrinolytics (tranexamic acid, aminocaproic acid) are generally contraindicated in DIC: blocking fibrinolysis in a fibrin-loaded microcirculation worsens organ ischemia. Exception: selected hyperfibrinolytic states such as APL, under specialist direction.
• Antithrombin and thrombomodulin concentrates are not routinely recommended in US practice; activated protein C (drotrecogin alfa) was withdrawn from the market and is no longer an option.

Hemorrhagic complications

• Intracranial hemorrhage — emergency. Consumption of platelets and fibrinogen plus plasmin-mediated factor V/VIII degradation; signals itself as new headache, pupillary asymmetry, or acute decline in mental status. Leading cause of early death in APL-associated DIC.
• Massive gastrointestinal or pulmonary hemorrhage — emergency. Falling hemoglobin, hematemesis, or frank blood in the endotracheal tube.
• **Adrenal hemorrhage (Waterhouse–Friderichsen syndrome)** — emergency. Bilateral adrenal microthrombosis with hemorrhagic infarction in meningococcemia; signals as refractory hypotension, hyponatremia, hyperkalemia, and hypoglycemia. Give stress-dose glucocorticoids.

Thrombotic/ischemic complications

• Purpura fulminans and acral gangrene — limb-threatening emergency. Dermal vessel thrombosis with acquired protein C deficiency; sharply demarcated retiform purpura progressing to black eschar.
• Acute kidney injury: glomerular and arteriolar fibrin deposition plus ischemic tubular necrosis; rising creatinine and oliguria despite adequate filling pressures.
• ARDS: pulmonary capillary microthrombi and diffuse alveolar damage; worsening hypoxemia with bilateral infiltrates not explained by volume overload.
• Multi-organ dysfunction syndrome, the final common pathway and the main driver of DIC's high mortality.

Treatment-related complications

• TACO and TRALI from plasma and platelet transfusion: new hypoxemia within hours of a product; TACO with elevated filling pressures, TRALI without.
• Citrate-induced hypocalcemia during massive transfusion: prolonged QT, tetany, worsening coagulopathy — ionized calcium must be monitored and repleted.
• Heparin-induced thrombocytopenia: a platelet drop occurring days after heparin exposure with new thrombosis; easy to mistake for worsening DIC — check the 4Ts and a PF4 assay.
• Bleeding from therapeutic heparin in a patient with unrecognized ongoing consumption.
• Differentiation (retinoic acid) syndrome from ATRA: fever, weight gain, hypoxemia, pulmonary infiltrates; treat with dexamethasone. ATRA may transiently worsen coagulopathy early in therapy.
• Ischemic worsening after antifibrinolytics, the reason they are avoided.

• The signature lab tetrad: thrombocytopenia + prolonged PT/aPTT + low fibrinogen + markedly elevated D-dimer, with schistocytes on smear. Low fibrinogen is what separates DIC from most other coagulopathies on a stem.
• DIC vs. TTP/HUS: both give schistocytes and thrombocytopenia, but TTP/HUS are platelet-plug microangiopathies — PT, aPTT, and fibrinogen are normal. If coagulation studies are normal, think ADAMTS13 deficiency, not DIC.
• DIC vs. liver disease: both prolong PT and lower platelets. Factor VIII is low in DIC and normal-to-high in liver failure because factor VIII is made by endothelium, not hepatocytes. This is the single most testable discriminator.
• DIC vs. vitamin K deficiency/warfarin: isolated prolongation of PT with normal fibrinogen and normal platelets; factors II, VII, IX, X down but V normal.
• APL is the association examiners love: Auer rods, t(15;17), PML-RARA, DIC at presentation. The single best next step is to start ATRA immediately on suspicion, before cytogenetics return — not to wait for confirmation and not to transfuse first.
• Purpura fulminans + fever + hypotension + hyponatremia/hyperkalemia = meningococcemia with Waterhouse–Friderichsen syndrome; give antibiotics and stress-dose steroids.
• Chronic, low-grade DIC with migratory superficial thrombophlebitis = Trousseau syndrome, classically pancreatic adenocarcinoma; treat with LMWH — warfarin characteristically fails.
• Common distractors: giving tranexamic acid to "stop the bleeding" (contraindicated in most DIC — it worsens microvascular ischemia); transfusing platelets or plasma purely to correct numbers in a non-bleeding patient; and calling heparin universally forbidden — it is actually indicated when thrombosis, not bleeding, dominates.